Afinitor pNet launch

























I would love to see the forecast model that justifies the development spend in Afinitor. A small share of RCC and then two rare tumor types. Start celebrating when SEGA breaks 75 scripts. A breast indication is the big hope or better yet wet dream
 






Plus side - FDA including the carcinoid description in the label. It will give the excuse for talking about it.

Down side - Try explaining how the OS interim analysis numerically
favored placebo enough to have the agency put it in the label.

good luck
 












I think there's considerably more profit potential in pNuts, as they are sold at all sports venues and many concert venues. A natural food low in sugar and high in protein.

Forget pNet, go with pNut!